NASDAQ:DNTH Dianthus Therapeutics Q3 2024 Earnings Report $101.00 -4.60 (-4.36%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$104.30 +3.30 (+3.27%) As of 07/20/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dianthus Therapeutics EPS ResultsActual EPS-$0.74Consensus EPS -$0.59Beat/MissMissed by -$0.15One Year Ago EPSN/ADianthus Therapeutics Revenue ResultsActual Revenue$2.17 millionExpected Revenue$1.07 millionBeat/MissBeat by +$1.10 millionYoY Revenue GrowthN/ADianthus Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeN/AConference Call DateThursday, November 7, 2024Conference Call Time4:00PM ETUpcoming EarningsDianthus Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Dianthus Therapeutics Earnings HeadlinesDianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 31,249 SharesJuly 14, 2026 | americanbankingnews.comDianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis MarketJuly 8, 2026 | tipranks.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. | Altimetry (Ad)Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)July 2, 2026 | globenewswire.comDianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia GravisJune 29, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Rhythm Pharmaceuticals (RYTM)June 18, 2026 | theglobeandmail.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
